Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and GI oncology diseases, ...

Reclassifying HFmrEF as a stable phenotype aims to reduce therapeutic inertia and GDMT underuse driven by heterogeneous ...

Heart failure is increasingly recognised as a syndrome driven not only by haemodynamic stress and neurohormonal dysregulation but also by chronic inflammation. In the injured myocardium, dead or ...

New research published in Nature Cardiovascular Research reveals that heart failure and atrial fibrillation share underlying genetic and molecular mechanisms, suggesting that the two cardiovascular ...

The human heart must constantly adapt to changing demands—a task that requires tightly coordinated molecular shuffling in ...

Dr. Sharma described space as a yin-yang environment that both accelerates tissue aging and degradation and provides an ideal setting for growing more complex, three‑dimensional heart tissues and ...

Using patient-derived cardiac tissue and stem cell-based models, the team of translational researchers demonstrated that targeting the genetic cause of disease improved cellular abnormalities and ...

Researchers headed by teams at Michigan Medicine and Mayo Clinic have discovered how a molecular process that occurs when donor hearts are preserved in cold storage contributes to failure after ...

Cardiovascular disease remains the world’s biggest killer, responsible for millions of deaths every year. Most heart attacks ...